Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mike Tankersley, Tonya Winders, Mark Aagren, Henrik Brandi, Mikkel Hasse Pedersen, Anne Sofie Ledgaard Loftager & Mette Bøgelund. (2021) Preference for Immunotherapy with Tablets by People with Allergic Rhinitis. Patient Preference and Adherence 15, pages 2539-2549.
Read now
Read now
Carlo Cavaliere, Cristoforo Incorvaia, Elona Begvarfaj, Maria Patrizia Orlando, Rosaria Turchetta, Angela Musacchio, Massimo Ralli, Andrea Ciofalo, Antonio Greco, Marco de Vincentiis & Simonetta Masieri. (2021) The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?. Expert Opinion on Drug Safety 20:3, pages 259-264.
Read now
Read now
Oliver Pfaar & Peter Socrates Creticos. (2018) Ragweed Sublingual Tablet Immunotherapy: Part II – Practical Considerations and Pertinent Issues. Immunotherapy 10:7, pages 617-626.
Read now
Read now
Articles from other publishers (26)
Marie‐Lee Simard, Natalija Novak, Jean‐Philippe Drolet, Marie‐Claude Joly, Hendrik Nolte, Eike Wuestenberg & Rémi Gagnon. (2023) Tolerability of sublingual versus vestibular allergy immunotherapy tablet administration: A randomized pilot study. Clinical & Experimental Allergy 54:2, pages 120-129.
Crossref
Crossref
Hendrik Nolte, Moisés A. Calderon, David I. Bernstein, Graham Roberts, Ryuji Azuma, Ruta Gronskyte Juhl & Veronica Hulstrøm. (2024) Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets. The Journal of Allergy and Clinical Immunology: In Practice 12:1, pages 85-95.e4.
Crossref
Crossref
Michael Blaiss, Lawrence DuBuske, Hendrik Nolte, Morten Opstrup & Karen Rance. (2023) A practical guide to prescribing sublingual immunotherapy tablets in North America for pediatric allergic rhinoconjunctivitis: an injection-free allergy immunotherapy option. Frontiers in Pediatrics 11.
Crossref
Crossref
Andreas Horn, David I. Bernstein, Kimihiro Okubo, Terrie Dalgaard, Ole Hels, Helle Frobøse Sørensen, Marianne Henriksen, Ryuji Azuma, Jan Mikler & Hendrik Nolte. (2023) House dust mite sublingual immunotherapy tablet safety in adolescents with allergic rhinoconjunctivitis. Annals of Allergy, Asthma & Immunology 130:6, pages 797-804.e2.
Crossref
Crossref
Tolly E.G. Epstein & Christopher W. Calabria. (2022) Is immunotherapy safe for treatment of severe asthma. Current Opinion in Allergy & Clinical Immunology 22:6, pages 396-401.
Crossref
Crossref
Lawrence DuBuske. (2022) Efficacy and safety of sublingual allergen immunotherapy. Allergy and Asthma Proceedings 43:4, pages 272-280.
Crossref
Crossref
K. Lam, J.M. Pinto, S.E. Lee, K. Rance & H. Nolte. (2022) Delivery options for sublingual immunotherapy for allergic rhinoconjunctivitis: clinical considerations for North America. Rhinology Online 5:5, pages 70-86.
Crossref
Crossref
Yashu Dhamija, Tolly E.G. Epstein & David I. Bernstein. (2022) Systemic Allergic Reactions and Anaphylaxis Associated with Allergen Immunotherapy. Immunology and Allergy Clinics of North America 42:1, pages 105-119.
Crossref
Crossref
Paroma Arefin, Md Shehan Habib, Mohammad Mostafa, Dipankar Chakraborty, reebash Chandra Bhattacharjee, Md Saidul Arefin & Debabrata Karmakar. (2021) Fexofenadine HCl Microspheres – Can it be the First Line therapy for Allergic Disorders ?. Biosciences Biotechnology Research Asia 18:4, pages 795-799.
Crossref
Crossref
Anne K. Ellis, Lori Connors, Marie-Josee Francoeur & Douglas P. Mack. (2021) Rupatadine to prevent local allergic reactions to sublingual allergy immunotherapy: a case series. Allergy, Asthma & Clinical Immunology 17:1.
Crossref
Crossref
Anne K. Ellis, Remi Gagnon, David I. Bernstein & Hendrik Nolte. (2021) Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis. Allergy, Asthma & Clinical Immunology 17:1.
Crossref
Crossref
Tilo Biedermann, Peter Couroux, Tina Maria Greve & Mika Mäkelä. (2021) Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trials. Allergy 76:12, pages 3733-3742.
Crossref
Crossref
Susan Waserman, Anita Shah & Ernie Avilla. (2021) Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis. Annals of Allergy, Asthma & Immunology 127:2, pages 165-175.e1.
Crossref
Crossref
Harold S. Nelson. (2021) The evolution of allergy immunotherapy. Annals of Allergy, Asthma & Immunology 126:4, pages 357-366.
Crossref
Crossref
Lubnaa Hossenbaccus, Sophia Linton, Sarah Garvey & Anne K. Ellis. (2020) Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
Moisés A. Calderon, Susan Waserman, David I. Bernstein, Pascal Demoly, Jo Douglass, Remi Gagnon, Constance H. Katelaris, Harold Kim, Harold S. Nelson, Yoshitaka Okamoto, Kimihiro Okubo, J. Christian Virchow, Lawrence DuBuske, Thomas B. Casale, G. Walter Canonica & Hendrik Nolte. (2020) Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report. The Journal of Allergy and Clinical Immunology: In Practice 8:9, pages 2920-2936.e1.
Crossref
Crossref
Kelsey Field & Michael S. Blaiss. (2020) Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations?. Current Allergy and Asthma Reports 20:9.
Crossref
Crossref
Hendrik Nolte, David I. Bernstein, Harold S. Nelson, Anne K. Ellis, Jörg Kleine-Tebbe & Susan Lu. (2020) Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. The Journal of Allergy and Clinical Immunology: In Practice 8:7, pages 2322-2331.e5.
Crossref
Crossref
Mike Tankersley, Joseph K. Han & Hendrik Nolte. (2020) Clinical aspects of sublingual immunotherapy tablets and drops. Annals of Allergy, Asthma & Immunology 124:6, pages 573-582.
Crossref
Crossref
Susanne Halken, Graham Roberts, Erkka Valovirta, Hendrik Nolte, Veronica Hulstrøm & Michael S. Blaiss. (2020) Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: Pooled Analyses of Clinical Trials. The Journal of Allergy and Clinical Immunology: In Practice 8:4, pages 1387-1393.e2.
Crossref
Crossref
Gunter Johannes Sturm, Christian Vogelberg, Miriam Marchon, Andreas Horn, Hans-Georg Vitzthum, Marco-Parwis Memar-Baschi & Jörg Kleine-Tebbe. (2019) Coadministration of Sublingual Immunotherapy Tablets and Management of Potential Adverse Effects: Austrian, German, and Swiss Expert Recommendations. Clinical Therapeutics 41:9, pages 1880-1888.
Crossref
Crossref
Joseph Cafone, Peter Capucilli, David A. Hill & Jonathan M. Spergel. (2019) Eosinophilic esophagitis during sublingual and oral allergen immunotherapy. Current Opinion in Allergy & Clinical Immunology 19:4, pages 350-357.
Crossref
Crossref
M. Klein, A. Magnan & G. Bouchaud. (2019) Nouvelle approche thérapeutique dans l’asthme : l’immunothérapie peptidique. Revue des Maladies Respiratoires 36:4, pages 442-446.
Crossref
Crossref
Hendrik Nolte, David I. Bernstein, Gordon L. Sussman, Bodil Svanholm Fogh, Susan Lu, Bernt Husøy & Harold S. Nelson. (2018) Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet. The Journal of Allergy and Clinical Immunology: In Practice 6:6, pages 2081-2086.e1.
Crossref
Crossref
David I. Bernstein, Joerg Kleine-Tebbe, Harold S. Nelson, Jose A. BardelasJrJr, Gordon L. Sussman, Susan Lu, Dorte Rehm, Bodil Svanholm Fogh & Hendrik Nolte. (2018) SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration. Annals of Allergy, Asthma & Immunology 121:1, pages 105-110.
Crossref
Crossref
Hendrik Nolte & Jennifer Maloney. (2018) The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Allergology International 67:3, pages 301-308.
Crossref
Crossref